Lophius Biosciences Raises €1.4M from Existing Investors

Lophius Biosciences, a Regensburg, Germany-based developer of novel T-cell-based diagnostic test systems, closed a €1.4m financing round.

All existing investors S-Refit, High-Tech Gründerfonds (HTGF) and Bayernkapital, which had led the company’s previous round (read here), participated in this financing.

Lophius intends to use the funds for the market introduction of its T-Track© CMV/EBV tests in the field of transplantation, for further development of a diagnostic test for the differential diagnosis of tuberculosis, as well as for the new development of a novel, blood-based multiple sclerosis test.

Led by CEO Dr. Michael Lutz, the company develops and markets innovative T-cell-based test systems for diagnostics and possible therapy control in the fields of transplantation, infection, and autoimmune diseases.



Join the discussion